Invention Grant
US08389724B2 Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative
有权
5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪衍生物的结晶盐形式
![Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative](/docs/US/2013-03-05/US08389724B2/abs.jpg.600x600.jpg)
- Patent Title: Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative
- Patent Title (中): 5,6,7,8-四氢-1,2,4-三唑并[4,3-a]吡嗪衍生物的结晶盐形式
-
Application No.: US13433629Application Date: 2012-03-29
-
Publication No.: US08389724B2Publication Date: 2013-03-05
- Inventor: Stephen Benedict David Winter , Monica Benito Velez , Ernesto Duran Lopez
- Applicant: Stephen Benedict David Winter , Monica Benito Velez , Ernesto Duran Lopez
- Applicant Address: ES Barcelona
- Assignee: Corporacion Medichem, S.L.
- Current Assignee: Corporacion Medichem, S.L.
- Current Assignee Address: ES Barcelona
- Agency: Cozen O'Connor
- Main IPC: C07D471/00
- IPC: C07D471/00
![Crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazine derivative](/abs-image/US/2013/03/05/US08389724B2/abs.jpg.150x150.jpg)
Abstract:
This invention provides a novel crystalline sitagliptin ethanedisulfonate salt having the structure set forth below, and a method for using same to treat type 2 diabetes.
Public/Granted literature
- US20120184558A1 Crystalline Salt Forms of a 5,6,7,8-Tetrahydro-1,2,4-Triazolo[4,3-a]Pyrazine Derivative Public/Granted day:2012-07-19
Information query
